Cargando…
The Duration of Coronavirus Disease 2019 (COVID-19) Clearance in Patients with Hematological Malignancies Can be Stratified By the Number of Chemotherapy Treatment and Severity of COVID-19
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The American Society of Hematology. Published by Elsevier Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665265/ http://dx.doi.org/10.1182/blood-2022-166433 |
| _version_ | 1784831253504065536 |
|---|---|
| author | Nishikubo, Masashi Shimomura, Yoshimitsu Nagai, Yuya Kondo, Tadakazu Ishikawa, Takayuki |
| author_facet | Nishikubo, Masashi Shimomura, Yoshimitsu Nagai, Yuya Kondo, Tadakazu Ishikawa, Takayuki |
| author_sort | Nishikubo, Masashi |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9665265 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | The American Society of Hematology. Published by Elsevier Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96652652022-11-16 The Duration of Coronavirus Disease 2019 (COVID-19) Clearance in Patients with Hematological Malignancies Can be Stratified By the Number of Chemotherapy Treatment and Severity of COVID-19 Nishikubo, Masashi Shimomura, Yoshimitsu Nagai, Yuya Kondo, Tadakazu Ishikawa, Takayuki Blood Online Publication Only The American Society of Hematology. Published by Elsevier Inc. 2022-11-15 2022-11-15 /pmc/articles/PMC9665265/ http://dx.doi.org/10.1182/blood-2022-166433 Text en Copyright © 2022 The American Society of Hematology. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Online Publication Only Nishikubo, Masashi Shimomura, Yoshimitsu Nagai, Yuya Kondo, Tadakazu Ishikawa, Takayuki The Duration of Coronavirus Disease 2019 (COVID-19) Clearance in Patients with Hematological Malignancies Can be Stratified By the Number of Chemotherapy Treatment and Severity of COVID-19 |
| title | The Duration of Coronavirus Disease 2019 (COVID-19) Clearance in Patients with Hematological Malignancies Can be Stratified By the Number of Chemotherapy Treatment and Severity of COVID-19 |
| title_full | The Duration of Coronavirus Disease 2019 (COVID-19) Clearance in Patients with Hematological Malignancies Can be Stratified By the Number of Chemotherapy Treatment and Severity of COVID-19 |
| title_fullStr | The Duration of Coronavirus Disease 2019 (COVID-19) Clearance in Patients with Hematological Malignancies Can be Stratified By the Number of Chemotherapy Treatment and Severity of COVID-19 |
| title_full_unstemmed | The Duration of Coronavirus Disease 2019 (COVID-19) Clearance in Patients with Hematological Malignancies Can be Stratified By the Number of Chemotherapy Treatment and Severity of COVID-19 |
| title_short | The Duration of Coronavirus Disease 2019 (COVID-19) Clearance in Patients with Hematological Malignancies Can be Stratified By the Number of Chemotherapy Treatment and Severity of COVID-19 |
| title_sort | duration of coronavirus disease 2019 (covid-19) clearance in patients with hematological malignancies can be stratified by the number of chemotherapy treatment and severity of covid-19 |
| topic | Online Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665265/ http://dx.doi.org/10.1182/blood-2022-166433 |
| work_keys_str_mv | AT nishikubomasashi thedurationofcoronavirusdisease2019covid19clearanceinpatientswithhematologicalmalignanciescanbestratifiedbythenumberofchemotherapytreatmentandseverityofcovid19 AT shimomurayoshimitsu thedurationofcoronavirusdisease2019covid19clearanceinpatientswithhematologicalmalignanciescanbestratifiedbythenumberofchemotherapytreatmentandseverityofcovid19 AT nagaiyuya thedurationofcoronavirusdisease2019covid19clearanceinpatientswithhematologicalmalignanciescanbestratifiedbythenumberofchemotherapytreatmentandseverityofcovid19 AT kondotadakazu thedurationofcoronavirusdisease2019covid19clearanceinpatientswithhematologicalmalignanciescanbestratifiedbythenumberofchemotherapytreatmentandseverityofcovid19 AT ishikawatakayuki thedurationofcoronavirusdisease2019covid19clearanceinpatientswithhematologicalmalignanciescanbestratifiedbythenumberofchemotherapytreatmentandseverityofcovid19 AT nishikubomasashi durationofcoronavirusdisease2019covid19clearanceinpatientswithhematologicalmalignanciescanbestratifiedbythenumberofchemotherapytreatmentandseverityofcovid19 AT shimomurayoshimitsu durationofcoronavirusdisease2019covid19clearanceinpatientswithhematologicalmalignanciescanbestratifiedbythenumberofchemotherapytreatmentandseverityofcovid19 AT nagaiyuya durationofcoronavirusdisease2019covid19clearanceinpatientswithhematologicalmalignanciescanbestratifiedbythenumberofchemotherapytreatmentandseverityofcovid19 AT kondotadakazu durationofcoronavirusdisease2019covid19clearanceinpatientswithhematologicalmalignanciescanbestratifiedbythenumberofchemotherapytreatmentandseverityofcovid19 AT ishikawatakayuki durationofcoronavirusdisease2019covid19clearanceinpatientswithhematologicalmalignanciescanbestratifiedbythenumberofchemotherapytreatmentandseverityofcovid19 |